

Product datasheet for TL306800V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

RAGE (AGER) Human shRNA Lentiviral Particle (Locus ID 177)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: RAGE (AGER) Human shRNA Lentiviral Particle (Locus ID 177)

Locus ID: 177

Synonyms: RAGE; SCARJ1; sRAGE

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: AGER - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001136, NM 001206929, NM 001206932, NM 001206934, NM 001206936,

NM 001206940, NM 001206954, NM 001206966, NM 172197, NR 038190, NM 001136.1, NM 001136.2, NM 001136.3, NM 001136.4, NM 172197.1, NM 172197.2, NM 001206954.1, NM 001206936.1, NM 001206940.1, NM 001206966.1, NM 001206934.1, NM 001206932.1,

NM 001206929.1, BC020669, BM971899

UniProt ID: Q15109

Summary: The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of

the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847). [provided by RefSeq,

May 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).